Literature DB >> 26556984

Inflammatory status in human hepatic cirrhosis.

María Martínez-Esparza1, María Tristán-Manzano1, Antonio J Ruiz-Alcaraz1, Pilar García-Peñarrubia1.   

Abstract

This review focuses on new findings about the inflammatory status involved in the development of human liver cirrhosis induced by the two main causes, hepatitis C virus (HCV) infection and chronic alcohol abuse, avoiding results obtained from animal models. When liver is faced to a persistent and/or intense local damage the maintained inflammatory response gives rise to a progressive replacement of normal hepatic tissue by non-functional fibrotic scar. The imbalance between tissue regeneration and fibrosis will determine the outcome toward health recovery or hepatic cirrhosis. In all cases progression toward liver cirrhosis is caused by a dysregulation of mechanisms that govern the balance between activation/homeostasis of the immune system. Detecting differences between the inflammatory status in HCV-induced vs alcohol-induced cirrhosis could be useful to identify specific targets for preventive and therapeutic intervention in each case. Thus, although survival of patients with alcoholic cirrhosis seems to be similar to that of patients with HCV-related cirrhosis (HCV-C), there are important differences in the altered cellular and molecular mechanisms implicated in the progression toward human liver cirrhosis. The predominant features of HCV-C are more related with those that allow viral evasion of the immune defenses, especially although not exclusively, inhibition of interferons secretion, natural killer cells activation and T cell-mediated cytotoxicity. On the contrary, the inflammatory status of alcohol-induced cirrhosis is determined by the combined effect of direct hepatotoxicity of ethanol metabolites and increases of the intestinal permeability, allowing bacteria and bacterial products translocation, into the portal circulation, mesenteric lymph nodes and peritoneal cavity. This phenomenon generates a stronger pro-inflammatory response compared with HCV-related cirrhosis. Hence, therapeutic intervention in HCV-related cirrhosis must be mainly focused to counteract HCV-immune system evasion, while in the case of alcohol-induced cirrhosis it must try to break the inflammatory loop established at the gut-mesenteric lymph nodes-peritoneal-systemic axis.

Entities:  

Keywords:  Alcohol; Cirrhosis; Cytokines; Hepatitis C virus; Inflammation; Liver; Macrophages

Mesh:

Substances:

Year:  2015        PMID: 26556984      PMCID: PMC4631958          DOI: 10.3748/wjg.v21.i41.11522

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  198 in total

1.  Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma.

Authors:  D K Hsu; C A Dowling; K C Jeng; J T Chen; R Y Yang; F T Liu
Journal:  Int J Cancer       Date:  1999-05-17       Impact factor: 7.396

2.  Acute phase proteins in the diagnosis and prediction of cirrhosis associated bacterial infections.

Authors:  Maria Papp; Zsuzsanna Vitalis; Istvan Altorjay; Istvan Tornai; Miklos Udvardy; Jolan Harsfalvi; Andras Vida; Janos Kappelmayer; Peter L Lakatos; Peter Antal-Szalmas
Journal:  Liver Int       Date:  2011-12-06       Impact factor: 5.828

Review 3.  EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.

Authors: 
Journal:  J Hepatol       Date:  2010-06-01       Impact factor: 25.083

4.  Deficient natural killer cell activity in alcoholic cirrhosis.

Authors:  B Charpentier; D Franco; L Paci; M Charra; B Martin; D Vuitton; D Fries
Journal:  Clin Exp Immunol       Date:  1984-10       Impact factor: 4.330

5.  M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease.

Authors:  Jinghong Wan; Merieme Benkdane; Fatima Teixeira-Clerc; Stéphanie Bonnafous; Alexandre Louvet; Fouad Lafdil; Françoise Pecker; Albert Tran; Philippe Gual; Ariane Mallat; Sophie Lotersztajn; Catherine Pavoine
Journal:  Hepatology       Date:  2013-11-20       Impact factor: 17.425

6.  NFkappaB, cytokines, TLR 3 and 7 expression in human end-stage HCV and alcoholic liver disease.

Authors:  Peter Stärkel; Christine De Saeger; Alastair J Strain; Isabelle Leclercq; Yves Horsmans
Journal:  Eur J Clin Invest       Date:  2010-07       Impact factor: 4.686

7.  Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis.

Authors:  Won-Il Jeong; Ogyi Park; Bin Gao
Journal:  Gastroenterology       Date:  2007-09-29       Impact factor: 22.682

8.  Lack of optimal T-cell reactivity against the hepatitis C virus is associated with the development of fibrosis/cirrhosis during chronic hepatitis.

Authors:  Jayaprakash Sreenarasimhaiah; Andrés Jaramillo; Jeffrey Crippin; Mauricio Lisker-Melman; William C Chapman; T Mohanakumar
Journal:  Hum Immunol       Date:  2003-02       Impact factor: 2.850

9.  Increased immunoglobulin A in alcoholic liver cirrhosis: exploring the response of B cells to Toll-like receptor 9 activation.

Authors:  B Massonnet; A Delwail; J-M Ayrault; C Chagneau-Derrode; J-C Lecron; C Silvain
Journal:  Clin Exp Immunol       Date:  2009-10       Impact factor: 4.330

10.  Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner.

Authors:  Golo Ahlenstiel; Rachel H Titerence; Christopher Koh; Birgit Edlich; Jordan J Feld; Yaron Rotman; Marc G Ghany; Jay H Hoofnagle; T Jake Liang; Theo Heller; Barbara Rehermann
Journal:  Gastroenterology       Date:  2009-09-10       Impact factor: 22.682

View more
  26 in total

Review 1.  Molecular mechanisms of the preventable causes of cancer in the United States.

Authors:  Erica A Golemis; Paul Scheet; Tim N Beck; Eward M Scolnick; David J Hunter; Ernest Hawk; Nancy Hopkins
Journal:  Genes Dev       Date:  2018-06-26       Impact factor: 11.361

2.  Impact of Cirrhosis on Resource Use and Inpatient Complications in Patients Undergoing Total Knee and Hip Arthroplasty.

Authors:  Jared M Newman; Nicholas K Schiltz; Christopher D Mudd; Caleb R Szubski; Alison K Klika; Wael K Barsoum
Journal:  J Arthroplasty       Date:  2016-04-27       Impact factor: 4.757

3.  B cell-activating factor is involved in thrombocytopenia in patients with liver cirrhosis.

Authors:  Takashi Satoh; Hayato Takiguchi; Haruki Uojima; Makoto Kubo; Chisato Tanaka; Fumiko Yokoyama; Naohisa Wada; Koji Miyazaki; Hisashi Hidaka; Chika Kusano; Masataka Kuwana; Ryouichi Horie
Journal:  Ann Hematol       Date:  2022-09-13       Impact factor: 4.030

Review 4.  Premenopausal Syndrome and NAFLD: A New Approach Based on Gender Medicine.

Authors:  Livianna Carrieri; Alberto Ruben Osella; Fausto Ciccacci; Gianluigi Giannelli; Maria Principia Scavo
Journal:  Biomedicines       Date:  2022-05-20

5.  Computed tomography (CT) and magnetic resonance imaging (MRI) of diffuse liver disease: a multiparametric predictive modelling algorithm can aid categorization of liver parenchyma.

Authors:  Ricardo Donners; Carmen Zaugg; Julian E Gehweiler; Tuyana Boldanova; Markus H Heim; Luigi M Terracciano; Daniel T Boll
Journal:  Quant Imaging Med Surg       Date:  2022-02

6.  MicroRNA-146a-5p Negatively Regulates Pro-Inflammatory Cytokine Secretion and Cell Activation in Lipopolysaccharide Stimulated Human Hepatic Stellate Cells through Inhibition of Toll-Like Receptor 4 Signaling Pathways.

Authors:  Yuhan Chen; Zhaochong Zeng; Xiaoyun Shen; Zhifeng Wu; Yinying Dong; Jason Chia-Hsien Cheng
Journal:  Int J Mol Sci       Date:  2016-07-07       Impact factor: 5.923

7.  Cirrhotic Cardiomyopathy: Another Case of a Successful Approach to Treatment of Hepatorenal Syndrome.

Authors:  Luis Otávio Mocarzel; Jessica Bicca; Luiza Jarske; Thamires Oliveira; Pedro Lanzieri; Ronaldo Gismondi; Mario Luiz Ribeiro
Journal:  Case Rep Gastroenterol       Date:  2016-10-10

8.  Down-regulation of common NFκB-iNOS pathway by chronic Thalidomide treatment improves Hepatopulmonary Syndrome and Muscle Wasting in rats with Biliary Cirrhosis.

Authors:  Tzu-Hao Li; Pei-Chang Lee; Kuei-Chuan Lee; Yun-Cheng Hsieh; Chang-Youh Tsai; Ying-Ying Yang; Shiang-Fen Huang; Tung-Hu Tsai; Shie-Liang Hsieh; Ming-Chih Hou; Han-Chieh Lin; Shou-Dong Lee
Journal:  Sci Rep       Date:  2016-12-23       Impact factor: 4.379

9.  CLIF-SOFA score and SIRS are independent prognostic factors in patients with hepatic encephalopathy due to alcoholic liver cirrhosis.

Authors:  Jin Hee Jeong; In Sung Park; Dong Hoon Kim; Seong Chun Kim; Changwoo Kang; Soo Hoon Lee; Tae Yun Kim; Sang Bong Lee
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

10.  Combination of Hypertension Along with a High Fat and Cholesterol Diet Induces Severe Hepatic Inflammation in Rats via a Signaling Network Comprising NF-κB, MAPK, and Nrf2 Pathways.

Authors:  Yuan Yuan; Hisao Naito; Xiaofang Jia; Kazuya Kitamori; Tamie Nakajima
Journal:  Nutrients       Date:  2017-09-14       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.